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Abstract 
Background: Tumor cells have evolved complex strategies to escape immune surveillance, a process which involves 
NK cells and T lymphocytes, and various immunological factors. Indeed, tumor cells recruit immunosuppressive cells 
[including regulatory T‑cells (Treg), myeloid‑derived suppressor cells (MDSC)] and express factors such as PD‑L1. 
Molecularly targeted therapies, such as imatinib, have off‑target effects that may influence immune function. Imatinib 
has been shown to modulate multiple cell types involved in anti‑cancer immune surveillance, with potentially detri‑
mental or favorable outcomes. Imatinib and other tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML) 
have dramatically changed disease course. Our study aimed to characterize the different populations of the immune 
system in patients with CML affected by their treatment.
Methods: Forty‑one patients with CML [33 treated with TKIs and 8 with TKIs plus interferon (IFN)‑α] and 20 controls 
were enrolled in the present study. Peripheral blood populations of the immune system [referred to as the overview 
of immune system (OVIS) panel, Treg cells and MDSCs] and PD‑1 expression were evaluated by flow cytometry. The 
immunological profile was assessed using the mRNA Pan‑Cancer Immune Profiling Panel and a NanoString nCounter 
FLEX platform.
Results: Patients receiving combination therapy (TKIs + IFN‑α) had lower numbers of lymphocytes, particularly T cells 
[838/µL (95% CI 594–1182)] compared with healthy controls [1500/µL (95% CI 1207 – 1865), p = 0.017]. These patients 
also had a higher percentage of Treg (9.1%) and  CD4+PD‑1+ cells (1.65%) compared with controls [Treg (6.1%) and 
 CD4+/PD‑1+(0.8%); p ≤ 0.05]. Moreover, patients treated with TKIs had more Mo‑MDSCs (12.7%) whereas those 
treated with TKIs + IFN‑α had more Gr‑MDSC (21.3%) compared to controls [Mo‑MDSC (11.4%) and Gr‑MDSC (8.48%); 
p ≤ 0.05].  CD56bright NK cells, a cell subset endowed with immune‑regulatory properties, were increased in patients 
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Background
Chronic myeloid leukemia (CML) is a clonal myelo-
proliferative disorder characterized by the presence of 
the oncogenic BCR-ABL1 fusion gene derived from the 
reciprocal translocation of the long arms of chromosome 
9 and chromosome 22 [1]. Disease course is typically 
triphasic, with the majority of patients presenting in the 
relatively stable chronic phase. However, if left untreated, 
patients with chronic-phase CML progress to accelerated 
phase and ultimately to blast crisis, which is invariably 
fatal [2].
The discovery of the unique molecular aberration of 
CML allowed the development of targeted therapies with 
tyrosine kinase inhibitors (TKIs), which revolutionized 
the management of CML in the late 1990s, offering the 
prospect of long-term disease control and near-normal 
life expectancy [3, 4]. Outside of clinical trials, three TKIs 
have been approved as front-line treatment for chronic-
phase CML, i.e., imatinib, nilotinib, and dasatinib [1]. 
Although response rates are excellent, between 10 and 
15% of CML patients fail to achieve adequate responses 
to multiple TKIs, due to the development of either resist-
ance or intolerance. Patients with the deepest responses 
might be eligible for treatment interruption, given the 
observation that up to 40% of them remain in remission 
following TKI cessation [5]. Until the advent of TKIs, 
interferon (IFN)-α was used as standard therapy for 
chronic-phase CML. Interestingly, the upfront adminis-
tration of TKIs and IFN-α, followed by low-dose IFN-α 
maintenance, enabled a high rate of imatinib discon-
tinuation in CML patients in major molecular response 
(MMR) [6].
During tumor development, cancer cells evolve 
complex strategies to elude immune surveillance, a 
process aimed at restraining cancer cell prolifera-
tion and involving multiple cell types, such as natural 
killer (NK) cells and T lymphocytes, and numerous 
immune factors, such as IL-2, tumor necrosis fac-
tor (TNF)-α and IFN-γ [7]. Furthermore, cancer cells 
can recruit immunosuppressive cells, such as tumor-
associated macrophages (TAM), regulatory T cells 
(Treg) and myeloid-derived suppressor cells (MDSCs) 
[8], and express or secrete immunosuppressive fac-
tors such as indoleamine 2,3-dioxygenase-1 (IDO1), 
and programmed death-ligand 1 (PD-L1) [9], all of 
which promote dysfunctional immune responses and 
shape a highly suppressive tumor microenvironment, 
ultimatey leading to exhaustion and/or apoptosis of 
PD-1-expressing cells via the activation of the PD-L1 
signalling pathway [8, 10, 11]. CML promotes a highly 
immune-suppressive tumor microenvironment, by 
favoring lymphocyte anergy or exhaustion, and induc-
ing the expansion of Treg cells and MDSCs [12, 13]. 
It has been shown that targeted anti-cancer thera-
pies with TKIs may also have off-target or immune-
mediated effects. For instance, imatinib modulates the 
function of multiple cell types involved in anti-cancer 
immune responses, with potentially detrimental as well 
as favorable outcomes [14]. The immunological effects 
of TKIs thus far described are diverse and include M2 
reprogramming of TAMs [15]; inhibition of dendritic 
cell (DC) recovery [16] and effector cytokine produc-
tion by  CD4+ T cells [17]; reduction of IgM-producing 
memory B cells [18]; T helper 1 (Th1) polarization [19]; 
triggering of NK function [20, 21]; down-regulation of 
IDO1 [22]; normalization of MDSC numbers [23] and 
impairment of Treg function [24].
The immune changes induced by TKIs and IFN-α in 
patients with CML have not been investigated previ-
ously and have important translational implications to 
optimize clinical trials of TKI discontinuation. Herein, 
we profiled the peripheral immunome of CML patients 
treated with TKIs alone or in combination with IFN-
α. We used the Overall Immune System (OVIS) stain-
ing panel for the flow cytometric assessment of key 
immune modulatory cell subsets, including Treg cells 
and MDSCs, and to quantify PD1 expression on T cells 
[25]. Additionally, we evaluated the blood immune 
transcriptome and we identified changes in immune 
gene expression profiles in patients treated with TKIs 
either alone or in combination with IFN-α. Taken 
together, our results suggest that TKIs in combination 
with IFN-α may promote an enhanced immune sup-
pressive state in patients with CML.
receiving TKIs plus IFN‑α compared with those treated with TKIs alone. Interestingly, serum IL‑21 was significantly 
lower in the TKIs plus IFN‑α cohort. Within the group of patients treated with TKI monotherapy, we observed that 
individuals receiving 2nd generation TKIs had lower percentages of  CD4+ Treg (3.63%) and Gr‑MDSC (4.2%) compared 
to patients under imatinib treatment  (CD4+ Treg 6.18% and Gr‑MDSC 8.2%), but higher levels of PD‑1‑co‑expressing 
 CD4+ cells (1.92%).
Conclusions: Our results suggest that TKIs in combination with IFN‑α may promote an enhanced immune suppres‑
sive state.
Keywords: Chronic myeloid leukemia, Interferon, Immunotherapy, Gene expression profiling, Immune monitoring
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Methods
Study population
Sixty-one subjects were enrolled in the present study 
(41 patients with CML and 20 healthy controls). The 
participants were recruited at Centro Hospitalar Uni-
versitário de Coimbra (CHUC) and Hospital Distrital 
da Figueira da Foz (HDFF, EPE), Portugal. Patients were 
grouped according to the specific treatment allocated 
(TKIs alone or TKIs plus IFN-α). Clinical and biological 
characteristics are summarized in Table  1. Treatment 
response criteria were defined according to the Euro-
pean Leukemia-Net (ELN) guidelines [1]. In the TKI 
group, 26 patients were classified as optimal respond-
ers and seven as a warning or failure. In the TKI plus 
IFN-α group, seven patients were classified as optimal 
responders and one patient as a warning. The study was 
conducted in accordance with the Helsinki Declaration, 
and all participants provided informed consent for par-
ticipation prior to enrolment. The Ethics Committee of 
the Faculty of Medicine (University of Coimbra, Portu-
gal) approved all research procedures.
Overview of immune system (OVIS) flow cytometry panel
Peripheral blood was collected into EDTA Vacutainers. 
We transferred 100 µL of whole blood into Trucount™ 
tubes (BD Biosciences) using reverse pipetting. Cells 
were stained using a 10-color panel, containing fluores-
cently labeled monoclonal antibodies (mAbs)  specific 
for the major immune cell populations. The OVIS panel 
included the following: anti-CD8 (FITC), anti-CD19 
(PE), anti-CD28 (ECD), anti-CD56 (PE-Cy5), anti-
CD3 (PE-Cy7), anti-CD45RA (APC), anti-CD14 (Alexa 
Fluor-700), anti-CD27 (APC eFluor-780), anti-CD45 
(Pacific Blue), and anti-CD4 (Krome Orange) mAbs. 
After a 15-min incubation at room temperature, eryth-
rocytes were lysed by BD Pharm Lyse™ reagent. Cells 
were run through a Gallios™ flow cytometer (Beck-
man Coulter), and data were analysed with the Kaluza 
Software (Beckman Coulter). The number of cells per 
microliter of whole blood was calculated as described 
by the manufacturer. For the Trucount method, 50 µL 
of mouse WB were added into Trucount tubes and pro-
cessed as per the manufacturer’s protocol, except for 
the lysis buffer used.
Isolation of peripheral blood mononuclear cells (PBMCs)
Peripheral blood mononuclear cells (PBMCs) were used 
for Treg and MDSC evaluation. PBMCs were separated 
from whole blood using density gradient centrifugation 
on Ficoll-Hypaque (GE Healthcare) according to the 
manufacturer’s protocol. After isolation, one aliquot of 
cells was used immediately, and the remaining aliquot 
was frozen (10 × 106 cells/vial) for Treg studies.
Regulatory T cell (Treg) assessment
Frozen PBMCs were thawed following the Cellular Tech-
nology Limited protocol (available online at http://www.
immun ospot .com). PBMCs were rested in RPMI-1640 
supplemented with CTL-Wash™ for 2 h at 37  °C before 
staining with the following mAbs in the Treg panel: anti-
PD-1 (FITC), anti-ICOS (PE), anti-CD3 (ECD), anti-
CD25 (PE-Cy5), anti-CD39 (PE-Cy7), anti-CD8 (Alexa 
Table 1 Biodemographic and  clinical characteristics 
of patients and controls
Characteristics CML patients Controls (n = 20)
TKI (n = 33) TKI + IFN-α 
(n = 8)
Demographic features
 Gender (%)
  Male 18 (54.5) 4 (50.0) 7 (35.0)
  Female 15 (45.5) 4 (50.0) 13 (65.0)
 Age (years)
  Median 63 50 58
  Range 37–84 34–62 30–89
Clinical features
 Age at diagnosis (years)
  Median 50 42
  Range 24–78 25–60
 Time of disease (years)
  Median 11.2 3.4
  Range 1.3–22.7 2.1–24.1
 Scoring systems
  Sokal score (n = 32) (n = 7)
  Low risk (%) 13 (40.6) 4 (57.1)
  Intermediate 
risk (%)
13 (40.6) 1 (14.3)
  High risk (%) 6 (18.8) 2 (28.6)
 Euro score (n = 32) (n = 7)
  Low risk (%) 14 (43.8) 5 (71.4)
  Intermediate 
risk (%)
17 (53.2) 2 (28.6)
  High risk (%) 1 (3.0) –
 Eutos score (n = 33) (n = 7)
  Low risk (%) 27 (81.8) 1 (14.3)
  High risk (%) 6 (18.2) 6 (85.7)
 Type of TKI
  Imatinib (%) 26 (78.8) 6 (75.0)
  Nilotinib (%) 1 (3.0) 2 (25.0)
  Dasatinib (%) 2 (6.1) –
  Bosutinib (%) 3 (9.1) –
  Ponatinib (%) 1 (3.0) –
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Fluor 700), anti-CD127 (APC eFluor 780), anti-CD4 
mAbs (Krome Orange) and anti-FoxP3 (eFluor 660). 
A LIVE/DEAD™ Fixable Violet solution was used to 
exclude dead cells from the analysis. Briefly, 1 × 106 cells 
were incubated for 10 min at 4 °C with FcR blocking rea-
gent. After washing with PBS, PBMCs were stained for 
cell surface markers at room temperature for 10  min. 
The LIVE/DEAD™ Fixable Violet solution dye was then 
added, and cells were incubated for 30 min at room tem-
perature. The FoxP3 Fix/Perm Kit was used for intracel-
lular staining of FoxP3 according to the manufacturer’s 
protocol.
Myeloid-derived suppressor cell (MDSC) evaluation
Immediately after isolation, 1 × 106 PBMCs were stained 
with the MDSC antibody panel, which included anti-
CD11b (PE), anti-CD33 (PE-Cy5), anti-CD15 (PE-Cy7), 
anti-arginase-1 (Alexa Fluor 700), and anti-CD45 (Pacific 
Blue) mAbs. Briefly, cells were incubated for 10  min at 
4 °C with FcR blocking reagent. After washing with PBS, 
PBMCs were stained for cell surface markers at room 
temperature for 15 min in the dark. Cells were then fixed 
and permeabilized with the Fix/Perm solution for 30 min 
at room temperature in the dark. After a further wash-
ing step, cells were stained with anti-arginase-1 mAbs for 
15 min at room temperature in the dark.
Targeted immune gene expression profiling
We used the nCounter™ FLEX platform (NanoString 
Technologies Inc., Seattle, WA) to assess immune tran-
scriptomic profiles in patient PBMCs [26]. The nCoun-
ter™ analysis system is a robust and highly reproducible 
method for detecting the expression of up to 800 genes 
in a single reaction with high sensitivity and linear-
ity across a broad range of expression levels [27]. It is 
based on digital detection and direct molecular barcod-
ing of individual target molecules through the use of a 
unique probe pair carrying 35- to 50-base target-specific 
sequences. This technology allows for direct multiplexed 
measurements of gene expression from a low amount of 
mRNA (25 to 300 ng) without the need for amplification 
by PCR. The RNA Pan-Cancer Immune Profiling Panel™, 
which includes 770 genes (109 cell surface markers for 
24 immune cell types, 30 cancer-testis antigens, > 500 
immune response genes, and 40 reference genes), was 
used in our experiments. Digital images were processed 
within the nCounter Digital Analyzer™ instrument, and 
the reporter probe counts, i.e., the number of times the 
color-coded barcode for that gene is detected, were tabu-
lated in a comma-separated value (CSV) format for data 
analysis with the nSolver™ software package. The analysis 
software automatically performs quality controls, nor-
malization, data analysis and creates reports with the 
options of performing advanced analyses, including path-
way applications [28]. The nCounter Advanced Analysis 
module (version 2.0.115) was used to calculate the rela-
tive abundance of immune cell types. The total lympho-
cyte score was defined as the average of the B cell, T cell, 
CD45, macrophage and cytotoxic T-cell scores. The other 
relative abundance scores were calculated by subtracting 
the total lymphocyte score from each cell type score. For 
instance, a NK-cell score will measure the relative abun-
dance of NK cells within the total immune population. 
Each score will increase by 1 when NK cells double their 
frequency relative to the 5 immune populations defining 
the total lymphocyte score.
Measurement of serum IL-21
Serum was harvested after the commencement of treat-
ment with either TKIs alone (n = 20 patients) or with 
TKIs and IFN-α (n = 8 patients) and from 12 healthy con-
trols. IL-21 was quantitated using commercially available 
reagents (IL-21 LEGEND MAX™ Human ELISA kit; Bio-
Legend, San Diego, CA; sensitivity: 4.2 pg/mL).
Statistical analyses
Dependent variables were logarithmically transformed to 
achieve an approximation to a normal distribution and 
to reduce heterogeneity. We tested the effect of the inde-
pendent variables on the measured parameters using lin-
ear models (LM). For each dependent variable, multiple 
pairwise comparisons were performed using sequential 
Bonferroni correction. Model validation was performed, 
for each LM, on the residuals by checking heterosce-
dasticity, normality, and influential observations. The 
results are expressed as estimated mean and 95% confi-
dence intervals (CI) unless otherwise stated. For correla-
tion analysis, the nonparametric Spearman rank test was 
used. All statistical comparisons were considered signifi-
cant when p values were < 0.05. Statistical analyses were 
performed using the IBM-SPSS® software package, ver-
sion 22.
Results
The overview of immune system (OVIS) analysis highlights 
differences between treatment groups
In order to evaluate whether treatment with TKIs, either 
alone or in combination with IFN-α, had an impact on 
immune cell populations in patients with CML, we ini-
tially assessed the frequency and absolute numbers of 
leukocyte subsets and immune cell populations using 
the OVIS antibody panel (Additional file 1 and Table 2) 
[25]. The degree of peripheral lymphopenia was higher 
in CML patients receiving TKIs plus IFN-α [1140/µL 
of blood (95% CI 811–1603)] compared with individu-
als receiving TKIs only [1853/µL (95% CI 1567–2191); 
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p = 0.039]. Not unexpectedly, patients treated with TKIs 
plus IFN-α had lower lymphocyte counts when com-
pared with healthy controls [2059/µL (95% CI 1660–
2554; p = 0.014)]. By contrast, no statistically significant 
differences were observed in granulocyte and monocyte 
counts (Table 2).
The numbers of circulating T cells and B cells, as 
defined by their expression of CD3 and CD19, respec-
tively, were not significantly different in the TKIs-only 
group compared with controls. Interestingly, the count 
of  CD3+ T cells was significantly lower in the TKIs plus 
IFN-α group [838/µL (95% CI 594–1182)] compared with 
controls [1500/µL (95% CI 1207–1865), p = 0.017]. We 
next categorized T-cell populations based on CD4 and 
CD8 expression and we also quantified functionally dis-
tinct naïve and memory  CD4+ and  CD8+ subsets (i.e., 
naïve T cells  [TN], central memory T cells  [TCM], effec-
tor memory T cells  [TEM] and terminally-differentiated 
effector memory T cells  [TEMRA]) using well established 
combinations of mAbs (Additional file 1) [29]. Although 
the  CD4+ T-cell compartment was marginally affected 
by treatment with TKIs alone, we observed a reduction 
of overall  CD4+ T-cell counts (p = 0.004), naïve  CD4+ 
T cells (p = 0.048) and  TCM cells (p = 0.026; Fig.  1a) in 
patients treated with TKIs and IFN-α compared with 
controls. Treatment with TKIs also translated into an 
increase of  CD8+  TEM and  CD8+  TEMRA compared with 
controls (p = 0.002 and p = 0.001, respectively). Finally, 
the absolute number of double-positive  CD4+CD8+ T 
cells was significantly lower in both treatment groups 
compared with controls, an effect which was more 
pronounced in the TKIs plus IFN-α group (p = 0.002; 
Table 2).
The number of NK cells was similar in blood sam-
ples from CML patients and controls. However, 
 CD56bright NK cells were significantly increased in 
patients receiving TKIs plus IFN-α compared with 
those treated with TKIs alone (p = 0.001; Fig. 1). Inter-
estingly, serum IL-21 levels were significantly lower in 
patients treated with TKIs and IFN-α compared with 
controls (Fig.  1b). We also observed a trend towards 
higher serum IL-21 levels in patients receiving TKIs 
Table 2 Overview of immune system (OVIS)
p value: statistical comparison vs control. p value # statistical comparison between TKIs and TKIs plus IFN-α. Cell populations with p < 0.050 are highlighted in italic
Cell populations Controls (n = 20) CML patients p value#
Mean 95% CI TKIs (n = 33) TKIs plus IFN-α (n = 8)
Mean 95% CI p value Mean 95% CI p value
Granulocytes 3971.9 (3195.1–4937.6) 3752.5 (3167.6–4445.3) 1.000 4051.7 (2872.1–5715.9) 1.000 1.000
Monocytes 328.7 (261.2–413.6) 381.5 (319.0–456.2) 0.930 466.4 (324.4–670.7) 0.326 0.973
CD45low 140.9 (104.5–189.9) 64.8 (51.4–81.8) 0.001 56.1 (35.0–90.0) 0.005 1.000
Lymphocytes 2059.4 (1660.5–2554.1) 1852.7 (1566.9–2190.8) 1.000 1140.3 (811.3–1602.6) 0.014 0.039
 B cells 241.9 (176.2–332.1) 147.9 (115.6–189.3) 0.052 171.6 (104.0–283.1) 0.751 1.000
 T cells 1500.3 (1207.0–1864.9) 1324.3 (1118.0–1568.7) 1.000 837.9 (594.1–1181.9) 0.017 0.060
  CD4+ 1016.4 (813.2–1270.4) 758.0 (637.1–901.7) 0.104 504.7 (354.7–718.1) 0.004 0.105
    Naive 358.5 (264.0–486.9) 230.7 (181.8–292.7) 0.067 173.1 (103.2–290.3) 0.048 0.573
    Central memory (CM) 344.3 (271.2–437.1) 238.3 (197.9–286.9) 0.047 183.8 (122.8–275.1) 0.026 0.475
    Effector memory (EM) 13.7 (6.9–27.1) 18.2 (10.7–31.0) 0.791 7.1 (2.2–22.6) 0.596 0.311
    EM CD45  RA+ (EMRA) 4.2 (2.1–8.1) 11.9 (7.0–20.1) 0.044 4.6 (1.5–14.3) 0.988 0.289
  CD8+ 207.1 (152.5–281.4) 327.7 (258.2–416.0) 0.055 193.2 (119.0–313.7) 0.968 0.132
    Naive 42.9 (29.1–63.2) 51.7 (38.2–69.8) 0.730 57.2 (31.0–105.5) 0.708 0.952
    Central memory (CM) 39.5 (28.7–54.3) 48.1 (37.5–61.6) 0.595 35.6 (21.5–58.9) 0.936 0.536
    Effector memory (EM) 5.2 (2.9–9.4) 19.7 (12.4–31.2) 0.002 10.5 (4.1–26.8) 0.411 0.454
    EM CD45  RA+ (EMRA) 13.3 (7.5–23.6) 74.7 (47.7–117.0) 0.001 23.0 (9.3–57.2) 0.566 0.060
  CD4+/CD8+ 228.3 (168.0–310.2) 126.3 (99.5–160.3) 0.009 82.0 (50.5–133.1) 0.002 0.253
 NK cells 243.4 (175.1–338.3) 233.4 (180.7–301.6) 1.000 159.1 (94.6–267.7) 0.517 0.573
  CD56Dim 243.3 (174.0–340.2) 266.2 (205.1–345.6) 0.906 135.8 (80.0–230.7) 0.159 0.067
  CD56Bright 11.2 (7.3–17.3) 6.3 (4.5–8.8) 0.092 28.6 (14.5 ‑ 56.5) 0.060 0.001
 CD56+ T cells 60.6 (36.9–99.6) 41.4 (28.1–61.0) 0.697 8.8 (4.0–19.4) 0.001 0.002
  CD4+ 14.0 (8.7–22.5) 7.9 (5.4–11.5) 0.154 2.4 (1.0–5.7) 0.002 0.039
  CD8+ 15.8 (9.3–26.8) 19.0 (12.4–29.1) 0.848 6.6 (2.5–17.3) 0.259 0.119
  CD4+/CD8+ 22.0 (13.4–36.3) 9.8 (6.6–14.7) 0.038 3.6 (1.4–8.9) 0.003 0.111
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Fig. 1 Frequency of immune cell types in patients with CML receiving TKIs, either alone or in combination with IFN‑α, and in healthy controls. a 
Pie charts summarizing the distribution of T cells,  CD4+ and  CD8+ major subsets, and NK cells in the blood of CML patients and healthy controls. 
 TCM = central memory T cell;  TEM = effector memory T cell;  TEMRA = terminally differentiated, effector memory T cell. b Serum IL‑21 levels in a 
subgroup of patients receiving either TKIs alone of TKIs in combination with IFN‑α, and in healthy controls. Results were compared with one‑way 
ANOVA with Tukey’s multiple comparisons test
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only compared with the combination therapy group. 
NKT cells, defined as CD56-expressing  CD3+ T cells, 
were significantly decreased in CML patients given 
TKIs plus IFN-α [8.8/µL (95% CI 4.0–19.4)] relative 
to controls [60.6/µL (95% CI 36.9–99.6), p = 0.001]. 
When analyzing CD4- and CD8-coexpressing  CD56+ 
T cells, we observed that the  CD4+ subset was pre-
dominantly reduced in patients receiving combination 
treatment with TKIs and IFN-α.
Taken together, these experiments suggest that the 
immune profile of patients treated with TKIs alone 
shows a greater similarity to that of age-matched 
healthy controls compared to the peripheral immu-
nome of patients receiving TKIs and IFN-α. Further-
more, patients given combination therapy showed a 
higher degree of lymphopenia, affecting both naïve 
and memory  CD4+ T cells.
Treatment with TKI plus IFN-α increases Treg cells in CML 
patients
We next measured Treg cells, defined by 
either a  CD3+CD4+CD25++FoxP3+ or a 
 CD3+CD8+CD25++FoxP3+ phenotype, in CML patients 
receiving TKIs alone or TKIs plus IFN-α, and in healthy 
controls. The percentage of bona fide Treg cells was 
increased in approximately 50% of CML patients treated 
with TKIs plus IFN-α compared with patients given TKIs 
alone (p = 0.001) and with healthy controls (p = 0.001) 
(Fig.  2a). We then attempted to correlate Treg numbers 
with TKI generation in patients receiving this treatment 
modality alone (Additional file  2). Patients treated with 
imatinib (a 1st generation TKI) had a higher frequency of 
blood Treg cells compared with patients treated with 2nd 
generation TKIs (6.18% versus 3.63%; p = 0.005) (Fig. 2b). 
Interestingly, patients treated with TKIs plus IFN-α 
Fig. 2 Regulatory T cells (Treg) in patients with CML receiving TKIs, either alone or in combination with IFN‑α, and in healthy controls. a Gating 
strategy used to identify blood Treg cells within the  CD4+ and  CD8+ T‑cell compartment. b Percentage of  CD4+ Treg cells in different patient 
groups (TKIs group, n = 33; TKIs plus IFN‑α group, n = 8) and in healthy controls (n = 20). c Frequency of  CD4+ Treg cells in patients with CML 
receiving imatinib (n = 26) or 2nd generation TKIs (n = 7). d Frequency of  CD8+ Treg cells in patients with CML receiving TKIs, either alone or in 
combination with IFN‑α, and in healthy controls. The p values in the figure reflect statistically significant differences among study groups
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showed a 3.4-fold increase of  CD8+ Treg cells compared 
with controls (p = 0.046; Fig.  2c). Using CD39 expres-
sion as a surrogate marker for Treg activation, we did 
not observe any differences in the activation status when 
comparing CML patients and controls (data not shown).
We also evaluated the expression of PD1 on both  CD4+ 
and  CD8+ T cells. As shown in Fig.  3,  CD4+ T cells 
expressed higher levels of PD1 in both CML treatment 
groups, with a statistically significant difference being 
detected when comparing patients on TKIs plus IFN-α 
and controls (1.65% versus 0.8%; p = 0.023; Fig.  3a). 
When restricting our analysis to the TKIs group, we 
observed that patients treated with 2nd generation TKIs 
had higher percentages of PD1-expressing  CD4+ T cells 
compared with patients receiving imatinib (1.92% ver-
sus 1.0%; p = 0.001) (Fig.  3b, Additional file  3). By con-
trast, we observed lower PD1 expression on the  CD8+ T 
cells of patients treated with TKIs plus IFN-α (p = 0.046; 
Fig. 3c).
MDSC levels are modulated by CML treatment
We next quantified granulocytic (Gr) MDSCs, 
defined as  CD45+CD11bbrightCD33dimCD15+Arg1+ 
cells, and monocytic-like (Mo) MDSCs, defined as 
 CD45+CD11bbrightCD33brightCD15negArg1neg cells, 
in CML patients and controls. Gr-MDSC levels were 
reduced in patients treated with TKIs relative to con-
trols, albeit differences failed to achieve statistical signifi-
cance (Fig. 4a). Interestingly, patients receiving TKIs plus 
IFN-α had 21.3% blood Gr-MDSCs on average, a pro-
portion that was significantly higher than that observed 
in the control group (p = 0.046) and in patients treated 
with TKIs only (p = 0.013; Fig. 4b). In contrast, the TKIs-
only patient group had the highest average level of Mo-
MDSCs (12.7%), followed by the TKIs plus IFN-α group 
(11.4%) and the control group (8.48%; p = 0.005; Fig. 4c). 
Finally, the ratio of Gr-MDSCs to Mo-MDSCs was 1.2 
in healthy individuals, 0.63 in patients treated with TKIs 
only (p = 0.042), and 2.56 in patients treated with TKIs 
plus IFN-α (p = 0.004; Fig. 4d).
When evaluating the impact of 1st generation and 
2nd generation TKIs on MDSC levels, we observed that 
the proportion of Gr-MDSC was significantly lower in 
patients receiving 2nd generation TKIs (p = 0.003; Fig. 5 
and Additional file 4). In contrast, Mo-MDSC levels were 
not affected. Although patient numbers are too low to 
allow definitive conclusions, it is interesting to note that 
two individuals treated with dasatinib showed the lowest 
levels of Gr-MDSCs and the highest levels of Mo-MDSCs 
(Additional file 4).
Transcriptomic analyses identify distinct immune gene 
expression profiles in the blood of CML patients treated 
with TKI and IFN-α
In a final set of experiments, we used the nCounter gene 
expression profiling platform to analyze the immune 
transcriptome of a subgroup of 20 CML patients from 
our initial cohort [30, 31]. Fourteen patients were 
assessed at various time points from the commence-
ment of TKIs and six patients were assessed on IFN-α 
therapy. Figure  6a shows the results of unsupervised 
hierarchical clustering of the immune cell type-specific 
scores generated by the nSolver™ software. A detailed 
list of genes used to identify each immune cell subset 
is available from a previous publication [32]. Patients 
treated with a combination of TKIs and IFN-α expressed 
lower levels of transcripts encoding molecules known 
to be expressed on cytotoxic T lymphocytes, Th1 cells, 
B cells and KIR-expressing  CD56dim NK cells. In addi-
tion, exhausted  CD8+ T cells were less represented in the 
blood of patients receiving TKIs plus IFN-α compared 
with patients treated with TKIs only. The transcrip-
tomic profile of patient #34 was markedly different from 
that of the two major clusters of CML patients, insofar 
Fig. 3 Programmed death receptor 1 (PD‑1) expression on  CD4+ and  CD8+ T cells in patients with CML receiving TKIs, either alone or in 
combination with IFN‑α, and in healthy controls. PD‑1 expression on  CD4+ (a, b) and  CD8+ T cells (c) from CML patients stratified by type of TKI 
used (imatinib or 2nd generation TKI). The p values in the figure reflect statistically significant differences among study groups
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as neutrophil-specific mRNA species and CD45 mRNA 
were highly expressed. A correlation matrix of immune 
cell type-specific scores, which reflects the co-expression 
patterns of immune-related mRNAs detected in patient 
blood, is shown in Fig.  6b. Interestingly, the expression 
of markers for exhausted  CD8+ T cells positively corre-
lated with that of  CD56dim NK cells, predominantly rep-
resenting KIR-expressing NK-cell populations [32]. We 
also analyzed signature scores which reflect the activa-
tion of relevant biological processes. As shown in Fig. 6c, 
our cohorts of CML patients could be clearly separated 
based on the expression profiles of specific gene modules. 
In particular, patients treated with a combination of TKIs 
plus IFN-α expressed lower levels of genes encoding NK 
function-associated molecules, interleukins and adhe-
sion molecules compared with patients treated with TKIs 
alone. This finding is in agreement with the observed 
reduction of serum IL-21 levels in patients on combina-
tion therapy (Fig.  1b). In contrast, the expression levels 
of genes associated with macrophage function, pathogen 
defense, T-cell function and cytokine/chemokine pro-
duction were higher after combination therapy. The cor-
relation matrix of signatures scores allowed us to identify 
co-expression and mutual exclusivity patterns of the 
Fig. 4 Frequency of myeloid‑derived suppressor cells (MDSCs) in patients with CML receiving TKIs, either alone or in combination with IFN‑α. 
a Gating strategy for the identification of granulocytic MDSCs (Gr‑MDSCs:  CD45+CD11bbrightCD33dimCD15+Arg1+) and monocytic‑like MDSCs 
(Mo‑MDSCs:  CD45+CD11bbrightCD33brightCD15negArg1neg). The frequency of Gr‑MDSCs (b), Mo‑MDSCs (c) and the ratio of Gr‑MDSCs to Mo‑MDSCs 
(d) are shown in CML patients and in healthy controls. Results are summarized as the mean ± SEM. The p values in the figure reflect statistically 
significant differences among study groups
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above gene modules (Fig.  6d). Not unexpectedly, differ-
ential expression (DE) analysis showed the induction of 
IFN pathway genes in patients receiving TKIs and IFN-α 
compared with patients treated with TKIs alone (Fig. 6e), 
including the over-expression of MX1, ISG15, IFIT1 and 
OAS3. The full list of differentially expressed genes is pro-
vided in Additional file 5.
Discussion
Several studies have demonstrated that the immunologi-
cal landscape of the tumor may affect treatment response 
[33, 34]. Particularly in CML, the main treatment goal 
is to achieve and sustain deep molecular responses that 
could lead to TKI discontinuation and to a state of treat-
ment-free remission [35]. Currently, approximately half 
of the patients with CML who discontinue TKI therapy 
relapse. In patients who achieve good clinical results, the 
success has generally been attributed to the re-activation 
of the immune system, which then effectively controls 
leukemia cell proliferation [36, 37].
The immunological profile of an individual patient 
is a dynamic process that is affected by several fac-
tors, including tumor cell characteristics, the tumor 
microenvironment and specific treatment modalities. 
Considering its susceptibility to immune system attack 
and the favorable results obtained with IFN-α in the 
pre-TKI era [38], CML qualifies as an ideal scenario for 
combination therapies with TKIs and IFN-α. This regi-
men has been shown to increase the rate of molecular 
responses in comparison with imatinib monotherapy 
[39]. Additionally, some authors have suggested the use 
of type I IFN at time of TKI discontinuation as a strategy 
to boost immune system responses [6, 40]. In our cohort 
of CML patients, treatment responses, as measured by 
BCR-ABL levels, were very satisfactory. However, the 
impact of long-term combination treatment on immune 
cell populations is presently unknown.
Herein, we present a comprehensive evaluation of the 
peripheral immunome of CML patients treated with TKI 
monotherapy or with TKIs plus IFN-α. Several immune 
subpopulations are reportedly increased at the time of 
diagnosis. However, the use of TKIs treatment has been 
shown  to reduce these proportions to levels that are 
similar to those observed in healthy subjects [41]. None-
theless, significant differences were found in immune 
cells associated with the disease as well as linked to the 
use of IFN in the therapeutic scheme. Antitumor effects 
of IFN-α are supported not only by the direct actions on 
Fig. 5 Frequency of myeloid‑derived suppressor cells (MDSCs) in patients with CML receiving imatinib or 2nd generation TKIs. The frequency of 
Gr‑MDSCs (a), Mo‑MDSCs (b) and the ratio of Gr‑MDSCs to Mo‑MDSCs (c) are shown in CML patients treated with imatinib or with 2nd generation 
TKIs. Results are summarized as the mean ± SEM. The p values in the figure reflect statistically significant differences among study groups
Fig. 6 Gene expression profiling of blood samples from patients with CML receiving TKIs, either alone or in combination with IFN‑α. a Unsupervised 
hierarchical clustering of immune cell type‑specific scores in patients treated with IFN‑α and TKIs or with TKIs alone. Data were analyzed and 
visualized using an on‑line resource (Morpheus; Broad Institute, MA, USA). b Correlation matrix (Pearson correlation coefficients) of immune cell 
type‑specific scores in patients treated with TKIs plus IFN‑α or with TKIs alone. Dark red denotes high correlation, dark blue denotes anti‑correlation 
and white denotes a lack of correlation. c Unsupervised hierarchical clustering of signature scores in patients treated with IFN‑α and TKIs or with TKIs 
alone. d Correlation matrix (Pearson correlation coefficients) of signature scores in patients treated with TKIs plus IFN‑α or with TKIs alone. Dark red 
denotes high correlation, dark blue denotes anti‑correlation and white denotes a lack of correlation. e Volcano plot showing differentially expressed 
(DE) genes in patients receiving IFN‑α and TKIs compared with patients treated with TKIs alone. The top DE genes (linear fold‑change > 4 or < 2 with 
a p value < 0.01) are highlighted in red (up‑regulated) and green (down‑regulated). The dotted horizontal lines indicate p values < 0.05 and < 0.01
(See figure on next page.)
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tumor cells (inhibition of cell proliferation and induction 
of apoptosis) but also by immune stimulation (enhancing 
T-cell activation, promoting DC maturation and stimu-
lating NK cell activity) [42, 43]. In accordance with this 
knowledge, we observed a higher count of  CD56bright 
NK cells in the combination group compared to TKIs in 
monotherapy.  CD56bright NK cells are considered to be 
regulatory NK cells that can exert beneficial or detrimen-
tal effects to the host, depending on the characteristics of 
the tissue microenvironment involved [44, 45]. Interest-
ingly, an early increase of  CD56bright NK cells has been 
documented in patients with multiple sclerosis receiving 
immunotherapy with daclizumab, an anti-CD25 mono-
clonal antibody [46, 47]. We also detected significantly 
lower levels of serum IL-21 in CML patients receiving 
TKIs and IFN-α, compared with healthy controls and 
with patients on TKIs only. IL-21 priming has previ-
ously been reported to boost NK-cell maturation in vitro 
in synergy with IL-15 [48]. Our observation therefore 
reinforces the contention that combination therapy with 
TKIs and IFN-α may induce an enhanced immunosup-
pressive state by also promoting the expansion of imma-
ture  CD56bright NK cells.
The transcriptomic analysis of blood samples col-
lected from CML patients allocated to  different treat-
ment modalities revealed high levels of genes encoding 
NK-function associated molecules (as KIR-expressing 
 CD56dim NK cells) and low levels of genes related to 
cytokine/chemokine production. By integrating immune 
cell quantification with high-dimensional flow cytometry 
and immune transcriptomic analyses, our study suggests 
that one possible mechanism of action for IFN-α may be 
related to the modulation of cytokine and chemokine 
production, therefore boosting adaptive immune 
responses. Some authors have reported that long-term 
exposure to imatinib and other TKIs promotes the 
expansion of circulating NK cells, a phenomenon which 
may favorably affect the outcome of TKI discontinuation 
[49, 50]. In our study, we did not detect any differences in 
NK-cell proportions in the TKI-only group, which were 
similar to those observed in the control population. Fur-
thermore, we found that IFN-α treatment in combina-
tion with TKI therapy induces a significant reduction in 
 CD56+ T cells.
CML as a chronic disease induces a state of immune 
dysfunction as well as T-cell exhaustion, mainly due to 
chronic stimulation of immune cells in an immunosup-
pressive microenvironment [41]. Several players may 
favor immune escape of cancer cells, including Treg cells 
and MDSCs, either directly or via the induction of inhibi-
tory receptors on effector cells [51]. Treg cells play an 
essential role in sustaining immunological unresponsive-
ness against tumor-associated antigens [52]. In several 
neoplasms, high percentages of Treg cells at the time of 
diagnosis or during treatment have been associated with 
a poor prognosis, including in hematological malignan-
cies [53]. Imatinib treatment may affect the function of 
Treg cells through the inhibition of IDO1 and by impair-
ing the expression of FoxP3, thus leading to Treg cell 
apoptosis [14, 24]. During TKI therapy, a reduction of 
Treg proportions to values similar to those in  healthy 
volunteers would be anticipated. Furthermore, IFN-α 
treatment reduced Treg numbers in patients with mela-
noma and renal cell carcinoma, tentatively attributable to 
the inhibition of IL-2 production which modulates Treg 
cell proliferation and activation [54]. Unexpectedly, the 
highest levels of Treg cells, both within the CD4 and the 
CD8 subset, were observed in the TKI plus IFN-α patient 
group in our study.
Current observations highlight the crosstalk between 
tumor cells, stroma and immune cells. An inflammatory 
microenvironment modulates normal myelopoiesis in 
favor of MDSCs, one of the most potent immunosup-
pressive cell subsets that may promote tumor progres-
sion. Modulation of Treg cells, up-regulation of PD-L1 
and release of molecules able to affect immune effector 
cells are some of the most critical MDSC functions thus 
far reported [55]. In CML, an increase in MDSCs at diag-
nosis has been observed and these cells were shown to 
be derived from a tumoral clone, as confirmed by BCR-
ABL expression [56]. According to current literature, 
both TKIs and IFN-α as monotherapy are able to reduce 
MDSC counts, probably as a result of maturation induc-
tion [33, 42]. Our data demonstrates that combinatorial 
therapy is  associated with higher levels of Gr-MDSCs 
compared with TKI monotherapy. In contrast, the TKIs-
only group showed the lowest levels of Gr-MDSCs but a 
significant increase of Mo-MDSCs. Chronic exposure to 
IFN-α in low doses may result in a suppressive environ-
ment through activation of MDSC cells [57]. The reduc-
tion on MDSC number by IFN-α, described by other 
authors, might be related to short-term treatment, and 
it is conceivable that long-term treatments would see the 
number of these cells increase again. Contrary to the low 
numbers expected, Stanojevic et  al. [42] described that 
the long-term effects of IFN-α on MDSC levels may differ 
from the short-term effects, as they observed a recovery 
of MDSC numbers. Collectively, our results show that 
the association of IFN-α to TKI therapy may drive a more 
suppressive environment supported by higher levels of 
Treg cells and MDSCs as well as more  CD4+PD1+ cells.
Another aspect explored in our study is whether differ-
ent types of TKIs may induce peculiar immune profiles. 
Patients treated with imatinib showed higher levels of 
Gr-MDSCs and  CD4+ Treg cells but lower proportions 
of  PD1+ cells compared to patients given 2nd generation 
Page 13 of 15Alves et al. J Transl Med            (2020) 18:2 
TKs. It has been shown that each TKI may differentially 
impact Treg, MDSC and  PD1+ cells, a phenomenon that 
could be explained by the different kinases targeted by 
each of them rather than BCR-ABL [40, 41]. For instance, 
dasatinib also targets the RC kinase which plays an 
important role in T and B-cell activation and prolifera-
tion [9, 33]. In fact, our results support that changes of 
immune cell frequencies may be related to the specific 
TKI used for treatment. In this respect, patients receiv-
ing 2nd generation TKIs showed higher proportions of 
exhausted  CD4+ T cells compared to patients receiving 
imatinib, an observation that could be accounted for by 
the inhibition of other signaling pathways.
Conclusions
Within the constraints of important limitations, includ-
ing the lack of functional data and the absence of experi-
ments using primary bone marrow samples, our study 
highlights the occurrence of immune modulation in 
patients receiving combination therapy with TKIs plus 
IFN-α and it also documents an impact of specific TKIs 
on different immune cell populations. Although the 
results shown here need to be validated in a larger cohort 
of CML patients, the administration of IFN-α might be a 
valuable strategy to boost immune surveillance, to pos-
sibly eradicate leukemic stem cells and to support TKI 
discontinuation, if associated with careful monitoring of 
immunosuppressive cells.
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